ストックスクリーナーアプリを入手
11.57
6.93%
0.75
前日終値:
$10.82
開ける：
$10.99
24時間の取引高:
14,993
Relative Volume:
0.16
時価総額：
$76.17M
収益：
-
当期純損益:
$-31.48M
株価収益率:
-11.12
EPS:
-1.04
ネットキャッシュフロー:
$-28.71M
1週間 パフォーマンス:
+13.71%
1か月 パフォーマンス:
+22.43%
6か月 パフォーマンス:
-3.58%
1年 パフォーマンス:
+49.29%
1日の値動き範囲:
$10.99
$11.79
1週間の範囲:
$9.91
$11.79
52週間の値動き範囲:
$4.11
$28.68
Forte Biosciences Inc Stock (FBRX) Company Profile
名前
Forte Biosciences Inc
セクター
電話
(310) 618-6994
住所
3060 PEGASUS PARK DRIVE, DALLAS, CA
FBRX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
FBRX
Forte Biosciences Inc
|
11.57 | 132.15M | 0 | -31.48M | -28.71M | -1.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
392.79 | 100.07B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.41 | 59.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
448.91 | 58.03B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
653.83 | 39.93B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
321.36 | 36.82B | 3.81B | -644.79M | -669.77M | -6.24 |
Forte Biosciences Inc Stock (FBRX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-01-21 | 開始されました | TD Cowen | Buy |
| 2024-04-08 | アップグレード | Ladenburg Thalmann | Neutral → Buy |
| 2021-09-20 | アップグレード | Chardan Capital Markets | Sell → Buy |
| 2021-09-03 | ダウングレード | B. Riley Securities | Buy → Neutral |
| 2021-09-03 | ダウングレード | Chardan Capital Markets | Buy → Sell |
| 2021-09-03 | ダウングレード | Ladenburg Thalmann | Buy → Neutral |
| 2021-09-03 | ダウングレード | Truist | Buy → Hold |
| 2021-05-14 | 開始されました | B. Riley Securities | Buy |
| 2021-03-26 | 開始されました | Citigroup | Buy |
| 2020-08-28 | アップグレード | Chardan Capital Markets | Neutral → Buy |
| 2020-08-25 | 開始されました | Truist | Buy |
すべてを表示
Forte Biosciences Inc (FBRX) 最新ニュース
What indicators show strength in Forte Biosciences Inc.July 2025 Decliners & Verified Momentum Stock Ideas - Newser
Is this a good reentry point in Forte Biosciences Inc.2025 Geopolitical Influence & Fast Entry Momentum Trade Alerts - Newser
Forte Biosciences Inc. Company’s Quarterly Earnings Growth: What the Numbers SayMarket Performance Report & Long-Term Capital Growth Strategies - Newser
Chardan Capital Reaffirms Buy Rating for Forte Biosciences (NASDAQ:FBRX) - Defense World
Automated trading signals detected on Forte Biosciences Inc.Trade Ideas & Verified Technical Signals - Newser
Long term hold vs stop loss in Forte Biosciences Inc.July 2025 Rallies & Comprehensive Market Scan Reports - Newser
Is Forte Biosciences Inc.’s ROIC above industry average2025 Market Outlook & Advanced Technical Signal Analysis - thegnnews.com
How to forecast Forte Biosciences Inc. trends using time seriesCEO Change & Smart Allocation Stock Reports - Newser
Reversal indicators forming on Forte Biosciences Inc. stockWeekly Profit Report & Daily Chart Pattern Signals - Newser
Real time social sentiment graph for Forte Biosciences Inc.Market Rally & Scalable Portfolio Growth Methods - Newser
Applying chart zones and confluence areas to Forte Biosciences Inc.2025 Performance Recap & Fast Entry High Yield Tips - Newser
Forte Biosciences (NASDAQ:FBRX) Raised to “Hold” at Wall Street Zen - Defense World
Short interest data insights for Forte Biosciences Inc.July 2025 Rallies & Short-Term High Return Strategies - Newser
Identifying reversal signals in Forte Biosciences Inc.Gap Down & Verified Momentum Stock Watchlist - Newser
FBRX: Chardan Capital Maintains Buy Rating, $61 Target Unchanged - AInvest
Using data filters to optimize entry into Forte Biosciences Inc.July 2025 Macro Moves & Free Expert Verified Stock Movement Alerts - Newser
Live market analysis of Forte Biosciences Inc.July 2025 Trends & Growth Oriented Trade Recommendations - Newser
Real time alert setup for Forte Biosciences Inc. performanceJuly 2025 Outlook & Fast Exit/Entry Strategy Plans - Newser
how forte biosciences inc. stock performs during market volatilityNew Guidance & Verified Swing Trading Watchlist - Newser
Relative strength of Forte Biosciences Inc. in sector analysisProfit Target & AI Powered Market Entry Strategies - Newser
Forte Biosciences: Chardan Capital raises Buy rating to $61, PT unchanged. - AInvest
This Forte Biosciences Insider Increased Their Holding By 273% Last Year - Yahoo Finance
What recovery options are there for Forte Biosciences Inc.2025 Breakouts & Breakdowns & Weekly Market Pulse Updates - Newser
Forte Biosciences Announces Q2 2025 Results and Trials - MSN
What MACD and RSI say about Forte Biosciences Inc.Analyst Downgrade & Consistent Profit Trade Alerts - Newser
How to build a custom watchlist for Forte Biosciences Inc.Quarterly Market Review & Fast Gain Stock Trading Tips - Newser
Forte Biosciences Tops Q2 Loss Forecasts - AOL.com
Forte Biosciences Announces Q2 Results and Business Update: Initiates 3 Clinical Trials for FB102 - AInvest
Forte Biosciences, Inc. Announces Results and Provides Update - The Joplin Globe
Forte Advances Treatment Pipeline for Celiac Disease, Vitiligo, and Alopecia with $106M War Chest - Stock Titan
Vitiligo Clinical Trial Pipeline Accelerates as 18+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight - GlobeNewswire Inc.
Using Python tools to backtest Forte Biosciences Inc. strategiesJuly 2025 Closing Moves & Target Return Focused Stock Picks - Newser
Using Ichimoku Cloud for Forte Biosciences Inc. technicalsRate Hike & Daily Growth Stock Investment Tips - Newser
Multi factor analysis applied to Forte Biosciences Inc.Intraday Price Action Forecast Planner - Newser
Analyzing Forte Biosciences Inc. with multi timeframe chartsShort Term Gain Strategy with AI Logic - Newser
Forte Biosciences (FBRX) to Release Earnings on Wednesday - Defense World
Forte Biosciences Inc (FBRX) 財務データ
収益
当期純利益
現金流量
EPS
Forte Biosciences Inc (FBRX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Wagner Paul A. | SEE REMARKS |
Jul 01 '25 |
Option Exercise |
0.00 |
1,250 |
0 |
81,038 |
| Riley Antony A | CHIEF FINANCIAL OFFICER |
Apr 01 '25 |
Option Exercise |
0.00 |
375 |
0 |
31,372 |
| Wagner Paul A. | SEE REMARKS |
Apr 01 '25 |
Option Exercise |
0.00 |
1,250 |
0 |
79,806 |
| Riley Antony A | CHIEF FINANCIAL OFFICER |
Jan 01 '25 |
Option Exercise |
0.00 |
375 |
0 |
31,151 |
| Wagner Paul A. | SEE REMARKS |
Jan 01 '25 |
Option Exercise |
0.00 |
1,250 |
0 |
78,720 |
| Riley Antony A | CHIEF FINANCIAL OFFICER |
Nov 21 '24 |
Buy |
5.55 |
22,514 |
124,998 |
30,776 |
| Riley Antony A | CHIEF FINANCIAL OFFICER |
Oct 01 '24 |
Option Exercise |
0.00 |
375 |
0 |
8,395 |
| Wagner Paul A. | SEE REMARKS |
Oct 01 '24 |
Option Exercise |
0.00 |
1,250 |
0 |
77,568 |
0.41%
0.88%
大文字化:
|
ボリューム (24 時間):